Maideen NMP. Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and P-gp efflux pump. World J Meta-Anal 2019; 7(4): 156-161 [DOI: 10.13105/wjma.v7.i4.156]
Corresponding Author of This Article
Naina Mohamed Pakkir Maideen, PhD, Doctor, Pharmacist, Pharmacologist, Department of Pharmacy, Dubai Health Authority, Al Maktoum Bridge Street, Dubai 4545, United Arab Emirates. nmmaideen@dha.gov.ae
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Meta-Anal. Apr 30, 2019; 7(4): 156-161 Published online Apr 30, 2019. doi: 10.13105/wjma.v7.i4.156
Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and P-gp efflux pump
Naina Mohamed Pakkir Maideen
Naina Mohamed Pakkir Maideen, Department of Pharmacy, Dubai Health Authority, Dubai 4545, United Arab Emirates
Author contributions: Maideen NMP solely contributed to this article.
Conflict-of-interest statement: There is no conflict of interest for this review.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Naina Mohamed Pakkir Maideen, PhD, Doctor, Pharmacist, Pharmacologist, Department of Pharmacy, Dubai Health Authority, Al Maktoum Bridge Street, Dubai 4545, United Arab Emirates. nmmaideen@dha.gov.ae
Telephone: +971-42-164952 Fax: +971-42-244302
Received: March 18, 2019 Peer-review started: March 18, 2019 First decision: April 13, 2019 Revised: April 21, 2019 Accepted: April 23, 2019 Article in press: April 23, 2019 Published online: April 30, 2019 Processing time: 43 Days and 20 Hours
Core Tip
Core tip: The probability of adverse drug interactions is higher among diabetic patients due to the concomitant administration of antidiabetic drugs with multiple medications to treat comorbidities such as hypertension, dyslipidemia, other cardiovascular problems, infections, depression, and others. Dipeptidyl peptidase 4 (DPP4) inhibitors are oral antidiabetic drugs approved to manage type 2 diabetes mellitus. Some of the DPP4 inhibitors have been identified as substrates of CYP3A4/5 enzymes and P-gp efflux pump. The drugs inhibiting or inducing CYP3A4/5 enzymes and/or P-gp can alter the pharmacokinetics of DPP4 inhibitors. The prescribers and the pharmacists are required to be aware of the drugs altering the pharmacokinetics of DPP4 inhibitors significantly to prevent adverse drug interactions.
